StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Monday, January 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Performance

Shares of Cytosorbents stock opened at $0.99 on Wednesday. The firm has a market capitalization of $54.13 million, a P/E ratio of -2.75 and a beta of 0.58. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a 50 day moving average price of $0.95 and a 200 day moving average price of $1.04.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, November 7th. The medical research company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The company had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. Sell-side analysts expect that Cytosorbents will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares in the last quarter. Atomi Financial Group Inc. acquired a new stake in Cytosorbents in the 3rd quarter valued at $51,000. Finally, Sargent Investment Group LLC grew its stake in Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after acquiring an additional 192,747 shares during the period. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.